Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
629 stopped studies mapped to Malignant Hepatobiliary Neoplasm and descendants · 92% state a reason
Over the 629 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06739252 | Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA | Phase 2 | terminated | Dec 18, 2024 | Peking University | Difficulty of participants enrollment | Enrollment / accrual |
| NCT05070247 | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced… | Phase 1 / Phase 2 | terminated | Oct 7, 2021 | Takeda | Clinical Futility of TAK 500 met. No further development with this compound | Efficacy / futility |
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally… | Phase 1 / Phase 2 | terminated | Feb 7, 2020 | Ocellaris Pharma, Inc. | Business Decision | Sponsor / business decision |
| NCT02917759 | Liver and Biliary Tumor Tissue Registry | — | terminated | Sep 28, 2016 | Mayo Clinic | Lack of funding to support enrollment | Enrollment / accrual |
| NCT05194072 | A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors | Phase 1 | terminated | Jan 18, 2022 | Seagen, a wholly owned subsidiary of Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety and/or… | Safety / toxicity |
| NCT04203160 | Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With… | Phase 1 / Phase 2 | terminated | Dec 18, 2019 | University of Michigan Rogel Cancer Center | Loss of funding | Funding |
| NCT04805788 | Stereotactic Body Proton Radiotherapy for the Treatment of Liver Cancer | Phase 2 | terminated | Mar 18, 2021 | Mayo Clinic | slow accrual | Enrollment / accrual |
| NCT06420349 | NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma | Phase 1 | terminated | May 20, 2024 | Mayo Clinic | study sponsor phasing out drug supply | Drug supply |
| NCT05044676 | Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for…(IMMUNOCELL) | — | terminated | Sep 16, 2021 | Assistance Publique - Hôpitaux de Paris | Abandon of study | Other (stated, no rule matched) |
| NCT05171166 | Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized… | Phase 2 / Phase 3 | terminated | Dec 28, 2021 | Peking University | Difficult to enroll participants | Enrollment / accrual |
| NCT05998447 | GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer | Phase 2 | terminated | Aug 21, 2023 | Genome & Company | Sponsor decision | Sponsor / business decision |
| NCT05427396 | A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004)… | Phase 1 | terminated | Jun 22, 2022 | Shanghai Junshi Bioscience Co., Ltd. | The trial was stopped early on the initiative of the sponsor on the basis of a change in the… | Safety / toxicity |
| NCT04779151 | Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and…(NIRADO) | Phase 2 | terminated | Mar 3, 2021 | Gustave Roussy, Cancer Campus, Grand Paris | Abandon of the partner, GSK | Other (stated, no rule matched) |
| NCT06320080 | Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of… | Phase 1 | terminated | Mar 20, 2024 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | This study was closed due to business reasons. Closure was not prompted by any safety or efficacy… | Safety / toxicity |
| NCT06994299 | A Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab…(PRISM) | Phase 2 | withdrawn | May 29, 2025 | Weill Medical College of Cornell University | Drug and financial support not available for the study. | Funding |
| NCT05256381 | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety… | Phase 2 | terminated | Feb 25, 2022 | SOTIO Biotech AG | Due to lack of expected efficacy shown at the time of the interim analysis | Efficacy / futility |
| NCT05194735 | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects… | Phase 1 / Phase 2 | terminated | Jan 18, 2022 | Alaunos Therapeutics | Funding | Funding |
| NCT02881554 | Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or… | N/A | terminated | Aug 29, 2016 | University of Washington | Terminated due to low accrual in Cohort B. (Accrual goal for Cohort A was met.) | Enrollment / accrual |
| NCT05033522 | Immunotherapy for Advanced Liver Cancer(ALIVE) | Phase 2 / Phase 3 | suspended | Sep 2, 2021 | Mirror Biologics, Inc. | Sponsor unable to fund | Funding |
| NCT05220722 | Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors | Phase 1 / Phase 2 | terminated | Feb 2, 2022 | TriSalus Life Sciences, Inc. | The decision was made to terminate the study after the completion of Phase 1b enrollment and not… | Safety / toxicity |
| NCT05229601 | A Study of HFB301001 in Adult Patients With Advanced Solid Tumors | Phase 1 | terminated | Feb 8, 2022 | HiFiBiO Therapeutics | The decision to discontinue the trial was made as part of a strategic review of the Sponsor's… | Safety / toxicity |
| NCT03144661 | An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced… | Phase 1 | terminated | May 9, 2017 | Incyte Corporation | Strategic Business Decision | Sponsor / business decision |
| NCT00422877 | Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary… | Phase 2 | terminated | Jan 17, 2007 | American Regent, Inc. | Sponsor suspended development of the drug on September 3, 2008. | Other (stated, no rule matched) |
| NCT04050462 | Nivolumab Combined With BMS-986253 in HCC Patients | Phase 2 | terminated | Aug 8, 2019 | NYU Langone Health | Study was terminated early by the drug sponsor due to slow accrual and a change in the company's… | Enrollment / accrual |
| NCT06302400 | Individualized Dosimetry for Holmium-166 Radioembolization in Patients With Unresectable…(RHEPaiR) | N/A | terminated | Mar 8, 2024 | Imperial College London | Terumo Europe NV permanently discontinued production of Holmium platform SIRT product range | Other (stated, no rule matched) |
| NCT05582018 | Safety and Effectiveness of BioTraceIO 360 for Planning, Monitoring and Assessment of…(PANORAMA) | N/A | terminated | Oct 17, 2022 | Techsomed Medical Technologies LTD | Sponsor decision | Sponsor / business decision |
| NCT06690281 | A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H… | Phase 2 | withdrawn | Nov 15, 2024 | National Cancer Institute (NCI) | PI left NIH. | Investigator |
| NCT04502082 | Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1) | Phase 1 | terminated | Aug 6, 2020 | Eureka Therapeutics Inc. | The trial was intended to be a Phase 1/2 trial, but the sponsor terminated the trial prior to… | Other (stated, no rule matched) |
| NCT06084689 | Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures(EMPIRE) | Phase 2 | withdrawn | Oct 16, 2023 | Institut Bergonié | Discontinuation of molecule development | Other (stated, no rule matched) |
| NCT05009979 | 18F-DCFPyL PET/CT in Hepatocellular Carcinoma | Phase 2 | terminated | Aug 18, 2021 | National Cancer Institute (NCI) | Reason for termination was a combination of slow accrual in setting of austerity measures regarding… | Enrollment / accrual |
| NCT05451862 | Holmium-166 Transarterial Radioembolization in Unresectable, Early Stage Hepatocellular…(HOMIE-166) | N/A | terminated | Jul 11, 2022 | Terumo Europe N.V. | The HOMIE-166 clinical investigation was prematurely terminated due to sponsor's decision to… | Sponsor / business decision |
| NCT02784795 | A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors | Phase 1 | terminated | May 27, 2016 | Eli Lilly and Company | The study was terminated due to business considerations | Sponsor / business decision |
| NCT04057365 | Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With… | Phase 2 | terminated | Aug 15, 2019 | Massachusetts General Hospital | Based on a Simon 2-stage design, this study did not meet response criteria to proceed to stage 2. | Other (stated, no rule matched) |
| NCT05975645 | A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib… | Phase 1 | terminated | Aug 4, 2023 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | This study was closed due to business reasons. Closure was not prompted by any safety or efficacy… | Safety / toxicity |
| NCT05124743 | HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T… | — | terminated | Nov 18, 2021 | Alaunos Therapeutics | TCR001-002 protocol was combined with TCR001-201 protocol, which was terminated due to business… | Sponsor / business decision |
| NCT03316872 | Study of Pembrolizumab and Radiotherapy in Liver Cancer | Phase 2 | terminated | Oct 20, 2017 | University Health Network, Toronto | The study was stopped due to the shift in systemic treatment paradigm for HCC precluding further… | Enrollment / accrual |
| NCT04571710 | A Trial of SHR1258 in Patients With Biliary Tract Cancer | Phase 2 | withdrawn | Oct 1, 2020 | Jiangsu HengRui Medicine Co., Ltd. | The sponsor's R\&D strategy is adjusted. | Sponsor / business decision |
| NCT07043348 | Streamlining Radioembolization for Intrahepatic Cholangiocarcinoma(ISTAR-04) | — | terminated | Jun 29, 2025 | Seoul National University Hospital | This study was merged with NCT07043387. Thus, this study was terminated. | Other (stated, no rule matched) |
| NCT04116320 | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors(AM-003) | Phase 1 | terminated | Oct 4, 2019 | Craig L Slingluff, Jr | Unable to enroll enough patients to complete targeted enrollment in a reasonable time. | Enrollment / accrual |
| NCT04561453 | Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer | — | terminated | Sep 23, 2020 | University of Washington | Study terminated due to end of funding | Funding |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | Phase 2 | terminated | Oct 3, 2022 | Telix Pharmaceuticals (Innovations) Pty Ltd | Indication scouting for TLX250-CDx will continue in theranostic studies, with a therapeutic… | Other (stated, no rule matched) |
| NCT04520906 | To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With… | N/A | terminated | Aug 20, 2020 | Suzhou Hengruihongyuan Medical Technology Co. LTD | Obtaining medical device market approval through the predicate device comparison route. | Other (stated, no rule matched) |
| NCT06572189 | The Safety and Efficacy of CD-801 in Patients With Advanced Intrahepatic… | Early Phase 1 | withdrawn | Aug 27, 2024 | Shanghai Changzheng Hospital | Based on the results of another intravenous injection therapy CD-801 for the treatment of… | Other (stated, no rule matched) |
| NCT05432193 | FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry… | Phase 1 | terminated | Jun 27, 2022 | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | Business decision | Sponsor / business decision |
| NCT06370663 | First-line Treatment for Unresectable Locally Advanced Distal Cholangiocarcinoma… | Phase 2 | terminated | Apr 17, 2024 | Shandong Cancer Hospital and Institute | Study was terminated due to unacceptable treatment-related toxicity that raised safety concerns and… | Safety / toxicity |
| NCT05630937 | Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable… | Phase 1 / Phase 2 | terminated | Nov 30, 2022 | Nerviano Medical Sciences | In the Phase II part of the study, among the participants evaluable for efficacy, no objective… | Efficacy / futility |
| NCT05342350 | International Study of High-Risk Patients for Hepatocellular Carcinoma Using Liquid Biopsy(STOP-HCC) | — | terminated | Apr 22, 2022 | Johns Hopkins University | PI moving on from current institution | Other (stated, no rule matched) |
| NCT05603572 | KAT-101 in Subjects With Hepatocellular Carcinoma (HCC) | Phase 1 / Phase 2 | suspended | Nov 2, 2022 | Primocure Pharma | Enrollment paused | Enrollment / accrual |
| NCT04152018 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | Phase 1 | terminated | Nov 5, 2019 | Pfizer | Study termination was based on strategic considerations and not due to specific safety reasons or a… | Safety / toxicity |
| NCT06361758 | Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC | Phase 2 | withdrawn | Apr 12, 2024 | Shanghai Zhongshan Hospital | The PI has initiated a global multicenter Phase II clinical trial in the same direction, conducted… | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Jan 28, 2026source: clinicaltrials